Market Overview

UPDATE: Wedbush Initiates Coverage on Curis on Potential of New Oral Therapies

Related CRIS
Curis Reports Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients with Advanced/Relapsed Solid Tumors
Events for the Week of Sept. 8-12

In a report published Friday, Wedbush analyst Christopher N. Marai initiated coverage on Curis (NASDAQ: CRIS) with an Outperform rating and $6.00 price target.

In the report, Wedbush noted, “Curis is a drug company developing oral therapies for oncology based on knowledge of cell signaling pathways. CRIS is developing CUDC-427, an antagonist of inhibitor of apoptosis proteins, key regulators of cancer cell death that may overcome chemotherapy resistance. It is also developing CUDC-907, a dual HDAC/PI3K inhibitor with differentiated PK/PD properties for DLBCL and MM. CRIS receives royalties from its partner Roche on sales of Erivedge, an approved hedgehog pathway inhibitor for advanced basal cell carcinoma.”

Curis closed on Thursday at $3.38.

Latest Ratings for CRIS

DateFirmActionFromTo
May 2014OppenheimerMaintainsOutperform
Dec 2013WedbushInitiates Coverage onOutperform
Dec 2013WedbushInitiates Coverage onOutperform

View More Analyst Ratings for CRIS
View the Latest Analyst Ratings

Posted-In: Christopher N. Marai WedbushAnalyst Color Initiation Analyst Ratings

 

Related Articles (CRIS)

Around the Web, We're Loving...

Get Benzinga's Newsletters